Antonio Di Biagio

List of Publications by Year
in descending order

362 papers	8,007 citations	109321 35 h-index	79698 73 g-index
376 all docs	376 docs citations	376 times ranked	12674 citing authors

#	Article	IF	Citations
1	Genetic mechanisms of critical illness in COVID-19. Nature, 2021, 591, 92-98.	27.8	1,014
2	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	13.7	627
3	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, The, 2019, 393, 143-155.	13.7	265
4	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV,the, 2015, 2, e98-e106.	4.7	249
5	ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. European Journal of Human Genetics, 2020, 28, 1602-1614.	2.8	208
6	Bloodstream infections in critically ill patients with COVIDâ€19. European Journal of Clinical Investigation, 2020, 50, e13319.	3.4	203
7	The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. Aids, 1999, 13, 2083-2089.	2.2	156
8	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Nonâ€“AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. Journal of Infectious Diseases, 2015, 211, 178-186.	4.0	146
9	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. ELife, 2021, 10, .	6.0	145
10	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809.	8.4	119
11	Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infectious Diseases, 2017, 17, 551.	2.9	112
12	Linezolid in the treatment of Gram-positive prosthetic joint infections. Journal of Antimicrobial Chemotherapy, 2005, 55, 387-390.	3.0	102
13	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 555.	2.4	93
14	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS ONE, 2020, 15, e0237831.	2.5	85
15	Multiclass <scp>HCV</scp> resistance to directâ€acting antiviral failure in realâ€life patients advocates for tailored secondâ€line therapies. Liver International, 2017, 37, 514-528.	3.9	84
16	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clinical Microbiology and Infection, 2020, 26, 1537-1544.	6.0	84
17	Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11970-11975.	7.1	73
18	Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infectious Diseases, 2017, 4, ofx239.	0.9	68

#	Article	IF	Citations
19	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patientâ€"A Case Study. Open Forum Infectious Diseases, 2021, 8, ofab217.	0.9	64
20	Treatment simplification to atazanavir/ritonavirâ€‰+â€‰lamivudine versus maintenance of atazanavir/ritonavirâ€‰+â€‰two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Journal of Antimicrobial Chemotherapy, 2017, 72, dkw557.	3.0	62
21	Prevalence, Awareness, Treatment, and Control Rate of Hypertension in HIV-Infected Patients: The HIV-HY Study. American Journal of Hypertension, 2014, 27, 222-228.	2.0	58
22	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896.	3.0	56
23	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy113.	0.9	56
24	Linezolid Treatment of Prosthetic Hip Infections due to Methicillin-resistant Staphylococcus aureus (MRSA). Journal of Infection, 2001, 43, 148-149.	3.3	54
25	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. Journal of Nephrology, 2021, 34, 173-183.	2.0	52
26	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine, 2021, 65, 103246.	6.1	52
27	Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum Î²-lactamase-producing organisms in an intensive care unit. Journal of Antimicrobial Chemotherapy, 2007, 60, 433-435.	3.0	47
28	Factors Associated With Weight Gain in People Treated With Dolutegravir. Open Forum Infectious Diseases, 2020, 7, ofaa195.	0.9	47
29	The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. Aids, 2020, 34, 877-881.	2.2	47
30	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	3.0	46
31	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. PLoS Pathogens, 2021, 17, e1009448.	4.7	43
32	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infectious Diseases, 2018, 18, 357.	2.9	42
33	Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. PLoS ONE, 2016, 11, e0164753.	2.5	41
34	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. Genes and Immunity, 2022, 23, 51-56.	4.1	41
35	The effect of formulary restriction in the use of antibiotics in an Italian hospital. European Journal of Clinical Pharmacology, 2001, 57, 529-534.	1.9	40
36	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 263-271.	2.1	39

#	Article	IF	Citations
37	Control of the HIV-1 DNA Reservoir Is AssociatedIn VivoandIn Vitrowith NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. Journal of Virology, 2017, 91, .	3.4	39
38	Bloodstream infections in HIV-infected patients. Virulence, 2016, 7, 320-328.	4.4	38
39	Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. Infection, 2017, 45, 849-856.	4.7	37
40	Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Annals of Pharmacotherapy, 2018, 52, 740-746.	1.9	36
41	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1â€“4 in Italy. Scientific Reports, 2018, 8, 8988.	3.3	36
42	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 39-47.	2.1	36
43	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. PLoS ONE, 2013, 8, e80157.	2.5	35
44	Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. European Journal of Human Genetics, 2021, 29, 745-759.	2.8	35
45	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiologica, 2010, 33, 195-206.	0.1	35
46	Evolution of transmitted HIVâ€1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. HIV Medicine, 2018, 19, 619-628.	2.2	34
47	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clinical Microbiology and Infection, 2016, 22, 288.e1-288.e8.	6.0	33
48	Bone Quality in Perinatally HIV-Infected Children: Role of Age, Sex, Growth, HIV Infection, and Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2005, 21, 927-932.	1.1	32
49	Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. Aids, 2010, 24, 1013-1018.	2.2	32
50	Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.5	32
51	Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy. International Journal of Antimicrobial Agents, 2000, 16, 295-299.	2.5	31
52	Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. Aids, 2009, 23, 534-538.	2.2	31
53	Novel antiretroviral drugs and renal function monitoring of HIV patients. AIDS Reviews, 2014, 16, 144-51.	1.0	31
54	Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. International Journal of Antimicrobial Agents, 2005, 26, 88-91.	2.5	30

#	Article	IF	Citations
55	Evolocumab in HIV-Infected Patients With Dyslipidemia. Journal of the American College of Cardiology, 2020, 75, 2570-2584.	2.8	30
56	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1955-1964.	3.0	29
57	Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. BMC Infectious Diseases, 2019, 19, 555.	2.9	29
58	Renal complications in HIV disease: between present and future. AIDS Reviews, 2012, 14, 37-53.	1.0	29
59	Raltegravir central nervous system tolerability in clinical practice. Aids, 2012, 26, 2412-2415.	2.2	28
60	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. Journal of Hepatology, 2018, 68, 597-600.	3.7	28
61	Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. International Journal of Antimicrobial Agents, 2004, 24, 83-84.	2.5	27
62	Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. Journal of Antimicrobial Chemotherapy, 2006, 57, 1168-1171.	3.0	27
63	Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. BMC Infectious Diseases, 2018, 18, 690.	2.9	27
64	Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy. Journal of Travel Medicine, 2020, 27, .	3.0	27
65	Factors associated with hospital admission for COVID-19 in HIV patients. Aids, 2020, 34, 1983-1985.	2.2	26
66	Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. Journal of Antimicrobial Chemotherapy, 2004, 54, 575-577.	3.0	25
67	Behind the screens: Clinical decision support methodologies â€“ A review. Health Policy and Technology, 2015, 4, 29-38.	2.5	25
68	HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users. PLoS ONE, 2016, 11, e0146097.	2.5	25
69	Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research, 2011, 3, 197.	1.9	24
70	Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. International Journal of Antimicrobial Agents, 2015, 45, 289-294.	2.5	24
71	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine, 2018, 16, 79.	5.5	24
72	Characterization of T lymphocytes in severe COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 5608-5613.	5.0	24

#	Article	IF	Citations
73	The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile . Drug Design, Development and Therapy, 2020, Volume 14, 5515-5520.	4.3	24
74	Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. BMC Infectious Diseases, 2021, 21, 353.	2.9	23
75	Candidainfections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Review of Anti-Infective Therapy, 2006, 4, 875-885.	4.4	22
76	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression. Aids, 2014, 28, 2269-2279.	2.2	22
77	â€˜Emergency exitâ€™ of bone-marrow-resident CD34+DNAM-1brightCXCR4+-committed lymphoid precursors during chronic infection and inflammation. Nature Communications, 2015, 6, 8109.	12.8	22
78	CD8+CD28â^'CD127loCD39+ regulatory T-cell expansion: AÂnew possible pathogenic mechanism for HIV infection?. Journal of Allergy and Clinical Immunology, 2018, 141, 2220-2233.e4.	2.9	22
79	Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. PLoS ONE, 2019, 14, e0223181.	2.5	22
80	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2018, 73, 177-182.	3.0	22
81	Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?. PLoS Neglected Tropical Diseases, 2017, 11, e0005237.	3.0	22
82	The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials. Medicine 2 0, 2013, 2, e5.	2.4	22
83	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. Human Genetics, 2022, 141, 147-173.	3.8	22
84	Effects of the Change From Stavudine to Tenofovir in Human Immunodeficiency Virus-Infected Children Treated With Highly Active Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2008, 27, 17-21.	2.0	21
85	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 1363-1367.	3.0	21
86	Clofazimine: an old drug for never-ending diseases. Future Microbiology, 2020, 15, 557-566.	2.0	21
87	Fatal lactic acidosis and mimicking Guillain-BarrÃ© syndrome in an adolescent with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 2003, 22, 668-670.	2.0	20
88	Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric caseâ€“control study. Journal of Bone and Mineral Metabolism, 2011, 29, 383-388.	2.7	20
89	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.9	20
90	From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care. AIDS Research and Human Retroviruses, 2018, 34, 239-240.	1.1	20

#	Article	IF	Citations
91	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. Journal of Medical Virology, 2014, 86, 1648-1655.	5.0	19
92	Major differences in organization and availability of health care and medicines for <scp>HIV/TB</scp> coinfected patients across <scp>E</scp>urope. HIV Medicine, 2015, 16, 544-552.	2.2	19
93	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. BMC Public Health, 2018, 18, 870.	2.9	19
94	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaÃ¯ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004â€“2014. HIV Medicine, 2019, 20, 99-109.	2.2	19
95	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiologica, 2012, 35, 17-25.	0.1	19
96	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiologica, 2017, 40, 86-98.	0.1	19
97	Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. Recent Patents on Anti-infective Drug Discovery, 2018, 13, 3-11.	0.8	18
98	How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. Journal of Clinical Virology, 2020, 123, 104255.	3.1	18
99	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmuL). HIV Medicine, 2004, 5, 1-10.	2.2	17
100	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS ONE, 2017, 12, e0179254.	2.5	17
101	Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infection and Drug Resistance, 2018, Volume 11, 615-623.	2.7	17
102	Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2012, 24, 54-58.	1.2	16
103	Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). Biomedicine and Pharmacotherapy, 2013, 67, 293-298.	5.6	16
104	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 735-741.	3.0	16
105	The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infection. BMC Infectious Diseases, 2014, 14, 277.	2.9	16
106	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. Journal of Infection, 2018, 76, 44-54.	3.3	16
107	Treatment of hepatitis C virus genotype 4 in the DAA era. Virology Journal, 2018, 15, 180.	3.4	16
108	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. Open Forum Infectious Diseases, 2020, 7, ofaa456.	0.9	16

#	Article	IF	Citations
109	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	5.8	16
110	HIV and tuberculosis: A historical perspective on conflicts and challenges. Tuberculosis, 2020, 122, 101921.	1.9	16
111	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infectionâ€"Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. Pathogens and Immunity, 2020, 5, 8.	3.1	16
112	Streptococcus pyogenes Erythromycin Resistance in Italy. Emerging Infectious Diseases, 1999, 5, 302-303.	4.3	15
113	Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir. AIDS Research and Human Retroviruses, 2006, 22, 132-138.	1.1	15
114	Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. Journal of Medical Case Reports, 2009, 3, 8136.	0.8	15
115	Transitioning HIV-infected Children and Adolescents into Adult Care: An Italian Real-life Experience. Journal of the Association of Nurses in AIDS Care, 2015, 26, 652-659.	1.0	15
116	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	8.1	15
117	Prevalence and determinants of resistance mutations in <scp>HIV</scp>â€1â€infected patients exposed to integrase inhibitors in a large Italian cohort. HIV Medicine, 2019, 20, 137-146.	2.2	15
118	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 119-127.	2.1	15
119	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. AIDS Patient Care and STDs, 2021, 35, 342-353.	2.5	15
120	Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: A European case control study. Clinical Nephrology, 2011, 75, 518-523.	0.7	15
121	Influence of indinavir and ritonavir on warfarin anticoagulant activity. Aids, 1998, 12, 825-6.	2.2	15
122	Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. Journal of Antimicrobial Chemotherapy, 2013, 68, 200-205.	3.0	14
123	Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Human Vaccines and Immunotherapeutics, 2015, 11, 263-269.	3.3	14
124	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. Journal of Antimicrobial Chemotherapy, 2019, 74, 3295-3304.	3.0	14
125	Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. Aids, 2020, 34, 53-61.	2.2	14
126	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The â€œImpACT-COVID-19 for Patientsâ€•Multi-Centre Observational Study. International Journal of Environmental Research and Public Health, 2021, 18, 340.	2.6	14

#	Article	IF	Citations
127	Risk for Nonâ€“AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. Annals of Internal Medicine, 2021, 174, 768-776.	3.9	14
128	96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience. PLoS ONE, 2012, 7, e39222.	2.5	13
129	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. Journal of Antimicrobial Chemotherapy, 2016, 71, 739-750.	3.0	13
130	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS ONE, 2017, 12, e0177352.	2.5	13
131	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine, 2018, 19, 475-484.	2.2	13
132	Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course. AIDS Research and Human Retroviruses, 2018, 34, 922-928.	1.1	13
133	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. AIDS Research and Therapy, 2019, 16, 11.	1.7	13
134	Therapeutical Aspects and Outcome of HIV/HCV Coinfected Patients Treated with Pegylated Interferon plus Ribavirin in an Italian Cohort. Infection, 2008, 36, 358-361.	4.7	12
135	The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs. HIV Clinical Trials, 2014, 15, 87-91.	2.0	12
136	Pegylated interferon Î± plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.9	12
137	Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. International Journal of Antimicrobial Agents, 2014, 43, 189-194.	2.5	12
138	Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. Epidemiology and Infection, 2018, 146, 606-611.	2.1	12
139	Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Pharmacoeconomics, 2019, 37, 255-266.	3.3	12
140	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3â€infected patients within the Italian network VIRONETâ€C. Liver International, 2021, 41, 1802-1814.	3.9	12
141	The impact of DAAâ€mediated HCV eradication on CD4⁺ and CD8⁺ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort. Journal of Viral Hepatitis, 2021, 28, 779-786.	2.0	12
142	Gram-positive bacterial resistance. A challenge for the next millennium. Panminerva Medica, 2002, 44, 179-84.	0.8	12
143	Penetration of didanosine in semen of HIV-1-infected men. Journal of Antimicrobial Chemotherapy, 2006, 57, 1244-1247.	3.0	11
144	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. Journal of Antimicrobial Chemotherapy, 2009, 64, 874-875.	3.0	11

#	Article	IF	Citations
145	Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. Journal of Chemotherapy, 2013, 25, 181-183.	1.5	11
146	Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. International Journal of Antimicrobial Agents, 2016, 48, 551-554.	2.5	11
147	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clinical Microbiology and Infection, 2017, 23, 267.e1-267.e4.	6.0	11
148	Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA). Journal of Clinical Virology, 2018, 105, 112-117.	3.1	11
149	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naÃ¯ve patients with CD4<200 cells/uL (the PRADAR study). PLoS ONE, 2019, 14, e0222650.	2.5	11
150	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Journal of Antimicrobial Chemotherapy, 2019, 74, 2732-2741.	3.0	11
151	Is the rate of virological failure to cART continuing to decline in recent calendar years?. Journal of Clinical Virology, 2019, 116, 23-28.	3.1	11
152	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. Journal of Clinical Virology, 2020, 130, 104534.	3.1	11
153	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. Viruses, 2020, 12, 791.	3.3	11
154	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. Infectious Diseases and Therapy, 2021, 10, 387-398.	4.0	11
155	Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. HIV Medicine, 2022, 23, 70-79.	2.2	11
156	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS ONE, 2017, 12, e0187393.	2.5	11
157	Inflammation Markers Correlate With Common Carotid Intima-Media Thickness in Patients Perinatally Infected With Human Immunodeficiency Virus 1. Journal of Ultrasound in Medicine, 2013, 32, 763-768.	1.7	11
158	Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. Journal of Preventive Medicine and Hygiene, 2013, 54, 83-6.	0.9	11
159	Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiologica, 2018, 41, 247-255.	0.1	11
160	Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. Vaccines, 2022, 10, 1141.	4.4	11
161	Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome. British Journal of Clinical Pharmacology, 1999, 48, 704-711.	2.4	10
162	Role of linezolid in the treatment of orthopedic infections. Expert Review of Anti-Infective Therapy, 2005, 3, 343-352.	4.4	10

#	Article	IF	Citations
163	Letter to the Editor: Successful Rescue Therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an HIV-Infected Patient Failing All Four Classes of Antiretroviral Drugs. AIDS Patient Care and STDs, 2008, 22, 355-357.	2.5	10
164	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. BioMed Research International, 2013, 2013, 1-9.	1.9	10
165	Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. Clinical Microbiology and Infection, 2013, 19, 936-942.	6.0	10
166	Gender differences in HIV infection: Is there a problem? Analysis from the SCOLTA cohorts. Biomedicine and Pharmacotherapy, 2014, 68, 385-390.	5.6	10
167	Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapyâ€“Experienced Patients: A Multicenter Clinical Experience. HIV Clinical Trials, 2014, 15, 140-150.	2.0	10
168	Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1â€“Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. HIV Clinical Trials, 2014, 15, 151-160.	2.0	10
169	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 2663-2669.	3.0	10
170	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA â‰¤50Âcp/mL. Infection, 2017, 45, 521-528.	4.7	10
171	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 2018, 13, 33.	1.5	10
172	Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. AIDS Research and Human Retroviruses, 2020, 36, 48-57.	1.1	10
173	Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database. Infection, 2015, 43, 339-343.	4.7	9
174	Undetectable <scp>HCV</scp>â€<scp>RNA</scp> at treatmentâ€week 8 results in highâ€sustained virological response in <scp>HCV</scp> G1 treatmentâ€experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. Journal of Viral Hepatitis, 2015, 22, 469-480.	2.0	9
175	Xpert HIV-1 Viral Load Assay and VERSANT HIV-1 RNA 1.5 Assay: A Performance Comparison. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e86-e88.	2.1	9
176	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. PLoS ONE, 2017, 12, e0181433.	2.5	9
177	THE MANAGEMENT OF GERIATRIC AND FRAIL HIV PATIENTS. A 2017 UPDATE FROM THE ITALIAN GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS AND THE DIAGNOSTIC-CLINICAL MANAGEMENT OF HIV-1 INFECTED PERSONS. Journal of Frailty & Aging,the, 2018, 8, 1-7.	1.3	9
178	Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortalityâ€"a multicentre prospective cohort study. BMC Infectious Diseases, 2021, 21, 1038.	2.9	9
179	HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy. Current Pharmaceutical Biotechnology, 2012, 13, 88-96.	1.6	8
180	Genotypic Determination of HIV Tropism in a Cohort of Patients Perinatally Infected With HIV-1 and Exposed to Antiretroviral Therapy. HIV Clinical Trials, 2014, 15, 45-50.	2.0	8

#	Article	IF	Citations
181	Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. ClinicoEconomics and Outcomes Research, 2015, 8, 15.	1.9	8
182	Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomedicine and Pharmacotherapy, 2015, 69, 233-236.	5.6	8
183	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clinical Infectious Diseases, 2016, 64, ciw846.	5.8	8
184	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 1637-1642.	3.0	8
185	Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. study-investigation on antiretroviral therapy). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1373-1377.	1.2	8
186	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	3.0	8
187	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. Clinical Microbiology and Infection, 2019, 25, 1443-1446.	6.0	8
188	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 681-689.	3.0	8
189	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. Microorganisms, 2020, 8, 2010.	3.6	8
190	SARS-CoV-2, alcohol consumption and liver injury. Minerva Medica, 2022, 113, .	0.9	8
191	Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19. Journal of Geriatric Cardiology, 2021, 18, 338-345.	0.2	8
192	Reversibility of Central Nervous System Adverse Events in Course of Art. Viruses, 2022, 14, 1028.	3.3	8
193	The organization of infection control in Italy. Journal of Hospital Infection, 2001, 48, 83-85.	2.9	7
194	Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally. Journal of Medical Virology, 2010, 82, 1110-1114.	5.0	7
195	Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). HIV Medicine, 2010, 11, 530-4.	2.2	7
196	A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen. BMC Medical Informatics and Decision Making, 2011, 11, 40.	3.0	7
197	Case report: Management and HBV sequencing in a patient coâ€infected with HBV and HIV failing tenofovir. Journal of Medical Virology, 2012, 84, 1340-1343.	5.0	7
198	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. Infection, 2014, 42, 61-71.	4.7	7

#	Article	IF	Citations
199	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS ONE, 2015, 10, e0124252.	2.5	7
200	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS ONE, 2015, 10, e0140877.	2.5	7
201	Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS. Patient Preference and Adherence, 2015, 9, 1213.	1.8	7
202	Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system. HIV Clinical Trials, 2015, 16, 190-196.	2.0	7
203	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e76-e79.	1.5	7
204	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. AIDS Patient Care and STDs, 2017, 31, 487-494.	2.5	7
205	How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. BMC Health Services Research, 2018, 18, 691.	2.2	7
206	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65Âyears with HCV genotype 1 cirrhosis. Infection, 2018, 46, 607-615.	4.7	7
207	Missed opportunities to prevent motherâ€toâ€child transmission of HIV in Italy. HIV Medicine, 2019, 20, 330-336.	2.2	7
208	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. Microorganisms, 2020, 8, 864.	3.6	7
209	Injectable Antiretroviral Drugs: Back to the Future. Viruses, 2021, 13, 228.	3.3	7
210	State of the Art of Dual Therapy in 2015. AIDS Reviews, 2015, 17, 127-34.	1.0	7
211	Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART. Journal of Antimicrobial Chemotherapy, 2005, 55, 1003-1007.	3.0	6
212	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007â€“2009. Clinical Microbiology and Infection, 2011, 17, 1352-1355.	6.0	6
213	Decreasing cardiovascular risk in HIV infection between 2005 and 2011. Aids, 2014, 28, 609-612.	2.2	6
214	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	3.0	6
215	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. PLoS ONE, 2017, 12, e0189425.	2.5	6
216	Bloodstream infections in patients living with HIV in the modern cART era. Scientific Reports, 2019, 9, 5418.	3.3	6

#	Article	IF	Citations
217	Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. AIDS Research and Human Retroviruses, 2020, 36, 19-26.	1.1	6
218	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. HIV Medicine, 2020, 21, 523-535.	2.2	6
219	Healthcare delivery for HIVâ€positive people with tuberculosis in Europe. HIV Medicine, 2021, 22, 283-293.	2.2	6
220	Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018. Frontiers in Pediatrics, 2021, 9, 665764.	1.9	6
221	Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir Â± ribavirin in HIV/HCV co-infected patients. PLoS ONE, 2018, 13, e0192627.	2.5	6
222	The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients. Current HIV Research, 2013, 11, 179-186.	0.5	6
223	Use of antibiotics in an Italian childrenâ€™s hospital, 1993â€“1995; clinical and economic considerations. International Journal of Antimicrobial Agents, 2000, 14, 33-37.	2.5	5
224	Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the Intensive Care Unit. International Journal of Antimicrobial Agents, 2006, 28, 582-585.	2.5	5
225	Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. Journal of Infection and Chemotherapy, 2012, 18, 587-590.	1.7	5
226	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. Journal of the International AIDS Society, 2014, 17, 19825.	3.0	5
227	Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients. Aids, 2014, 28, 1071-1074.	2.2	5
228	Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome. Digestive and Liver Disease, 2015, 47, 157-163.	0.9	5
229	Inpatient admissions of patients living with HIV in two European centres (UK and Italy); comparisons and contrasts. Journal of Infection, 2015, 70, 690-694.	3.3	5
230	Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports. International Journal of STD and AIDS, 2015, 26, 831-834.	1.1	5
231	Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study. Epidemiology and Infection, 2017, 145, 1658-1669.	2.1	5
232	Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study. Virulence, 2017, 8, 101-108.	4.4	5
233	One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. Aids, 2017, 31, 375-384.	2.2	5
234	Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. ERJ Open Research, 2018, 4, 00108-2017.	2.6	5

#	Article	IF	Citations
235	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. PLoS ONE, 2018, 13, e0190302.	2.5	5
236	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). AIDS Research and Therapy, 2019, 16, 21.	1.7	5
237	Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection. Annals of Internal Medicine, 2020, 172, 297.	3.9	5
238	Reply to: â€œAntiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19â€. Open Forum Infectious Diseases, 2020, 7, ofaa321.	0.9	5
239	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS ONE, 2016, 11, e0160761.	2.5	5
240	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. AIDS Reviews, 2017, 19, .	1.0	5
241	New antibiotics for treatment of serious infections due to antibiotic-resistant Gram-positive cocci. Reviews in Medical Microbiology, 2004, 15, 109-117.	0.9	4
242	Benign Lymphoepithelial Parotid Lesions in Vertically HIV-Infected Patients. AIDS Patient Care and STDs, 2006, 20, 536-541.	2.5	4
243	Feasibility and Reproducibility of HIV-1 Genotype Resistance Test in Very-Low-Level Viremia. Antimicrobial Agents and Chemotherapy, 2014, 58, 7620-7621.	3.2	4
244	Incidence and factors associated with the risk of sexually transmitted diseases in <scp>HIV</scp>â€infected people seen for care in <scp>I</scp>taly: data from the <scp>I</scp>cona <scp>F</scp>oundation cohort. HIV Medicine, 2015, 16, 412-420.	2.2	4
245	Disseminated Histoplasmosis with Mucocutaneous Immune Reconstitution Inflammatory Syndrome in an HIV-Infected Patient. AIDS Research and Human Retroviruses, 2015, 31, 274-275.	1.1	4
246	Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program. Journal of Hepatology, 2016, 64, S763.	3.7	4
247	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 465-471.	2.1	4
248	Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?. BMC Infectious Diseases, 2017, 17, 127.	2.9	4
249	Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 281-293.	1.9	4
250	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. BMC Public Health, 2019, 19, 1291.	2.9	4
251	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1857-1865.	2.9	4
252	Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821882165.	1.5	4

#	Article	IF	Citations
253	Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 496-503.	2.1	4
254	High doses of hydroxychloroquine do not affect viral clearance in patients with SARSâ€CoVâ€2 infection. European Journal of Clinical Investigation, 2020, 50, e13358.	3.4	4
255	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 132-137.	2.1	4
256	State of the Art of Dual Therapy in 2015. AIDS Reviews, 2017, 17, .	1.0	4
257	Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort. Journal of Personalized Medicine, 2022, 12, 188.	2.5	4
258	Fatal lactic acidosis and mimicking Guillain-BarrÃ© syndrome in an adolescent with human immunodeficiency virus infection. Pediatric Infectious Disease Journal, 2003, 22, 668-70.	2.0	4
259	Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. New Microbiologica, 2017, 40, 139-142.	0.1	4
260	Clinically Stable Treatment-Experienced Adults Receiving Tenofovir and Didanosine. HIV Clinical Trials, 2006, 7, 10-15.	2.0	3
261	Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. Infection, 2007, 35, 451-456.	4.7	3
262	Infectious complications of cancer chemotherapy in HIV patients. Current Infectious Disease Reports, 2008, 10, 149-156.	3.0	3
263	Different evidence of key amprenavir resistance mutations on the efficacy of darunavir. Aids, 2008, 22, 437-438.	2.2	3
264	Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. European Journal of Medical Research, 2009, 14, 136.	2.2	3
265	Lamivudine resistance mutations in European patients with hepatitis B and patients coâ€infected with HIV and hepatitis B. Journal of Medical Virology, 2011, 83, 1905-1908.	5.0	3
266	Inflammation Markers Correlate With Common Carotid Intima-Media Thickness in Patients Perinatally Infected With Human Immunodeficiency Virus 1. Journal of Ultrasound in Medicine, 2013, 32, 763-768.	1.7	3
267	Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates. Journal of Chemotherapy, 2016, 28, 337-340.	1.5	3
268	HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 189-193.	1.4	3
269	Is a step-down antiretroviral therapy necessary to fight severe acute respiratory syndrome coronavirus 2 in HIV-infected patients?. Aids, 2020, 34, 1865-1867.	2.2	3
270	Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3698-3699.	3.0	3

#	Article	IF	Citations
271	Enhancing care for people living with HIV: current and future monitoring approaches. Expert Review of Anti-Infective Therapy, 2021, 19, 443-456.	4.4	3
272	Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?. Human Vaccines and Immunotherapeutics, 2021, 17, 1664-1665.	3.3	3
273	Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature. Clinical Nephrology Case Studies, 2018, 6, 31-35.	0.7	3
274	IANUA: a regional project for the determination of costs in HIV-infected patients. Studies in Health Technology and Informatics, 2015, 210, 241-5.	0.3	3
275	Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents. New Microbiologica, 2017, 40, 227-233.	0.1	3
276	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 668-670.	2.0	2
277	Tenofovir use in a patient with a severe renal impairment. HIV Medicine, 2004, 5, 450-451.	2.2	2
278	Persistence ofCandida albicansCandidemia in Non-Neutropenic Surgical Patients: Management of a Representative Patient in the Absence of Second-Line Treatment Guidelines. Journal of Chemotherapy, 2007, 19, 335-338.	1.5	2
279	Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA)â€. Clinical Microbiology and Infection, 2013, 19, E443-E446.	6.0	2
280	Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL. Journal of the International AIDS Society, 2014, 17, 19718.	3.0	2
281	Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?. Recent Patents on Anti-infective Drug Discovery, 2014, 9, 41-51.	0.8	2
282	Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy. Aids, 2015, 29, 2061-2062.	2.2	2
283	Role of HCV-RNA decay and IP-10 levels after 48hours of standard HCV therapy as predictors of rapid virological response. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 705-710.	1.5	2
284	Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection. Clinical Infectious Diseases, 2016, 62, 1323.1-1323.	5.8	2
285	Onychomadesis in a male patient with secondary syphilis. International Journal of STD and AIDS, 2016, 27, 704-705.	1.1	2
286	Immunisation practices in centres caring for children with perinatally acquired HIV: A call for harmonisation. Vaccine, 2016, 34, 5587-5594.	3.8	2
287	Effectiveness of first-generation HCV protease inhibitors. European Journal of Gastroenterology and Hepatology, 2016, 28, 37-41.	1.6	2
288	Brief Report: Drop in CD4+ Counts Below 200 Cells/Î¼L After Reaching (or Starting From) Values Higher than 350 Cells/Î¼L in HIV-Infected Patients With Virological Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 417-422.	2.1	2

#	Article	IF	Citations
289	Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy. Antiviral Therapy, 2018, 23, 633-637.	1.0	2
290	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naÃ¯ve, HIV-1-infected patients. HIV Clinical Trials, 2018, 19, 158-162.	2.0	2
291	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. Current Hypertension Reviews, 2018, 14, 48-55.	0.9	2
292	A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice. AIDS Reviews, 2019, 20, 75-82.	1.0	2
293	Is it time to re-think the use of etravirine in patients with available genotypic resistance test?. Infectious Diseases, 2019, 51, 452-455.	2.8	2
294	The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e17-e21.	2.1	2
295	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. PLoS ONE, 2020, 15, e0240550.	2.5	2
296	The role of hepatitis B vaccine challenge dose in patients with underlying health conditions. Human Vaccines and Immunotherapeutics, 2021, 17, 575-579.	3.3	2
297	Buruli ulcer in a traveller returning from Madagascar: the first report of Mycobacterium ulcerans infection from the region. Journal of Travel Medicine, 2021, 28, .	3.0	2
298	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.9	2
299	Children living with HIV in Europe: do migrants have worse treatment outcomes?. HIV Medicine, 2022, 23, 186-196.	2.2	2
300	Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. Recent Patents on Anti-infective Drug Discovery, 2019, 13, 190-197.	0.8	2
301	Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children. BMC Infectious Diseases, 2022, 22, 55.	2.9	2
302	Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. New Microbiologica, 2014, 37, 439-48.	0.1	2
303	Prevalence and Risk Factors for Significant Liver Fibrosis in Patients with HIV Infection. In Vivo, 2015, 29, 771-5.	1.3	2
304	A Web Based Tool to Enhance Monitoring and Retention in Care for Tuberculosis Affected Patients. Studies in Health Technology and Informatics, 2017, 237, 204-208.	0.3	2
305	Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV. AIDS Research and Human Retroviruses, 2022, 38, 472-479.	1.1	2
306	Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment. Frontiers in Immunology, 2022, 13, 847816.	4.8	2

#	Article	IF	Citations
307	Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2. Journal of Community Health, 2022, 47, 800-805.	3.8	2
308	Consecutive blood lactate assessment in HIV-infected children: correlation with therapy and clinical characteristics. International Journal of Infectious Diseases, 2005, 9, 173-175.	3.3	1
309	Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children. International Journal of Antimicrobial Agents, 2007, 29, 228-230.	2.5	1
310	Evaluation of insulin resistance in a cohort of HIV-infected youth. Current Diabetes Reports, 2009, 9, 260-261.	4.2	1
311	Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone. Clinical and Experimental Immunology, 2009, 158, 55-63.	2.6	1
312	Nevirapine-Based Regimens in Routine Clinical Settings: Results from a Large Italian Cohort of HIV-1 Infected Adults. Current Drug Safety, 2011, 6, 138-144.	0.6	1
313	Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection. Journal of Chemotherapy, 2012, 24, 56-58.	1.5	1
314	Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. Indian Journal of Pediatrics, 2014, 81, 856-60.	0.8	1
315	Quality of Life Among Hiv Patients: Results from the Ianua Clinical Trial. Value in Health, 2015, 18, A592.	0.3	1
316	Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2Âyears. European Journal of Pediatrics, 2015, 174, 843-846.	2.7	1
317	In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment. Journal of Hepatology, 2016, 64, S419-S420.	3.7	1
318	Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc. International Journal of STD and AIDS, 2017, 28, 1067-1073.	1.1	1
319	Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies. Digestive and Liver Disease, 2017, 49, e49-e50.	0.9	1
320	Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. AIDS Research and Human Retroviruses, 2018, 34, 168-170.	1.1	1
321	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. Frontiers in Immunology, 2018, 9, 2447.	4.8	1
322	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load â‰¤50 copies/mL: does estimated glomerular filtration rate matter?. International Journal of Antimicrobial Agents, 2020, 56, 106154.	2.5	1
323	HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting. International Journal of Environmental Research and Public Health, 2020, 17, 9010.	2.6	1
324	Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. Tuberculosis, 2021, 126, 102041.	1.9	1

#	Article	IF	Citations
325	Evaluating fostemsavir as a therapeutic option for patients with HIV. Expert Opinion on Pharmacotherapy, 2021, 22, 1539-1545.	1.8	1
326	General Practitioners as partners for a shared management of chronic HIV infection: An insight into the perspectives of Italian People Living with HIV. PLoS ONE, 2021, 16, e0254404.	2.5	1
327	Migrants and imported disease: Trends of admission in an Italian infectious disease ward during the migration crisis of 2015â€“2017. BMC Public Health, 2020, 20, 738.	2.9	1
328	Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study. Journal of Medical Virology, 2022, , .	5.0	1
329	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. Sexually Transmitted Infections, 2022, , sextrans-2021-055289.	1.9	1
330	Fluoroquinolones in the Treatment of Atypical Mycobacterial Infections in AIDS. Drugs, 1999, 58, 402-403.	10.9	0
331	Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors. Digestive and Liver Disease, 2014, 46, e45.	0.9	0
332	P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS. Journal of Hepatology, 2014, 60, S500-S501.	3.7	0
333	Budget Impact Analysis of Sofosbuvir-Based Regimens for The Treatment of Hiv/Hcv Co-Infected Patients In Northern Italy: The Liguria Region Simulation. Value in Health, 2015, 18, A579-A580.	0.3	0
334	Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient. AIDS Research and Human Retroviruses, 2015, 31, 868-869.	1.1	0
335	Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents. Digestive and Liver Disease, 2016, 48, e1-e2.	0.9	0
336	Influence of HIV-1 Co-Receptor Tropism on Liver Fibrosis in HIV-Infected Patients. Journal of Hepatology, 2016, 64, S716-S717.	3.7	0
337	Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies. Journal of Hepatology, 2016, 64, S626-S627.	3.7	0
338	Commentary: Human Immunodeficiency Virus and Allergic Bronchopulmonary Aspergillosis. Open Forum Infectious Diseases, 2016, 3, ofw192.	0.9	0
339	Exophytic Lesion of the Tongue in a Patient with Undetectable HIV-RNA in the Past 3 Years. AIDS Research and Human Retroviruses, 2017, 33, 19-20.	1.1	0
340	Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy. Digestive and Liver Disease, 2017, 49, e62-e63.	0.9	0
341	HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life. Digestive and Liver Disease, 2017, 49, e53.	0.9	0
342	PIN112 - HEALTH TECHNOLOGY ASSESSMENT OF THE AVAILABLE NRTI BACKBONES IN ITALY. Value in Health, 2018, 21, S239.	0.3	0

#	Article	IF	Citations
343	Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment. Aids, 2018, 32, 1202-1203.	2.2	0
344	Modulation of the Natural Killer Cell Compartment during DAAs treatment in Interferon-naÃ¯ve HCV patients: The type of DAA matters. Immunology Letters, 2018, 203, 112-115.	2.5	0
345	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. Journal of Virus Eradication, 2019, 5, 47-49.	0.5	0
346	Response to letter to the editor. Aids, 2019, 33, 2263-2264.	2.2	0
347	Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. Journal of Women and Aging, 2019, 31, 176-188.	1.0	0
348	Marked decrease in acquired resistance to antiretrovirals in latest years in Italy. Clinical Microbiology and Infection, 2020, 27, 1038.e1-1038.e6.	6.0	0
349	Tuberculosis treatment outcomes in a rural area of Senegal: a decade of experience from 2010 to 2019 by StopTB Italia. Future Microbiology, 2021, 16, 399-407.	2.0	0
350	Comments on â€œRealâ€world reâ€treatment outcomes of directâ€acting antiviral therapy failure in patients with chronic hepatitis Câ€. Journal of Medical Virology, 2022, 94, 436-438.	5.0	0
351	Darunavir-based dual therapy in HIV experienced patients. Journal of the International AIDS Society, 2014, 17, 19782.	3.0	0
352	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	2.5	0
353	Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare.. JHA - Journal of HIV and Ageing, 2019, , .	0.0	0
354	Cause di ricovero ed outcome del paziente con infezione da HIV nei reparti di terapia intensiva.. JHA - Journal of HIV and Ageing, 2019, , .	0.0	0
355	The Italian registry of pulmonary nontuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 0, , .	1.5	0
356	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. Journal of Virus Eradication, 2019, 5, 47-49.	0.5	0
357	The impact of PrEP: results from a multicenter Health Technology Assessment into the Italian setting. Journal of Preventive Medicine and Hygiene, 2020, 61, E451-E463.	0.9	0
358	Reuse of Clinical COVID-19 Patient Data: Pre-Processing for Future Classification. Studies in Health Technology and Informatics, 2020, 275, 117-121.	0.3	0
359	Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen. AIDS Research and Human Retroviruses, 2021, , .	1.1	0
360	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0

#	Article	IF	Citations
361	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0
362	The Ligurian HIV Network: How Medical Informatics Standards Can Help Clinical Research. Studies in Health Technology and Informatics, 2019, 264, 1666-1667.	0.3	0